Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Gerald P Miletello"'
Autor:
Elizabeth I. Buchbinder, Janice P. Dutcher, Gregory A. Daniels, Brendan D. Curti, Sapna P. Patel, Shernan G. Holtan, Gerald P. Miletello, Mayer N. Fishman, Rene Gonzalez, Joseph I. Clark, John M. Richart, Christopher D. Lao, Scott S. Tykodi, Ann W. Silk, David F. McDermott
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Abstract Background Metastatic melanoma (mM) and renal cell carcinoma (mRCC) are often treated with anti-PD-1 based therapy, however not all patients respond and further therapies are needed. High dose interleukin-2 (HD IL-2) can lead to durable resp
Externí odkaz:
https://doaj.org/article/2501d6126ef24a80bcbed81058801563
Autor:
Ralph J. Hauke, Richard L. White, Douglas B. Johnson, Ajjai Alva, Theodore F. Logan, Elizabeth J. Davis, Peter H. Wiernik, Gerald P Miletello, Asim Amin, Howard L. Kaufman, Brendan Curti, Joseph I. Clark, Ulka N. Vaishampayan, Janice P. Dutcher
Publikováno v:
Journal of Investigative Medicine
High-dose interleukin-2 (HD IL-2) was approved in the 1990s after demonstrating durable complete responses (CRs) in some patients with metastatic melanoma (mM) and metastatic renal cell carcinoma (mRCC). Patients who achieve this level of disease con
Autor:
Scott S. Tykodi, Brendan Curti, J. Treisman, Neeraj Agarwal, Nancy C. Gregory, Janice P. Dutcher, Gregory A. Daniels, Michael Ka Keu Wong, Gerald P Miletello, David F. McDermott, Ralph J. Hauke, Michael A. Morse, Howard L. Kaufman, Helen Moon, Joseph I. Clark, Ajjai Alva, Kathleen M. Mahoney, Mayer Fishman
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Background Prognostic scoring systems are used to estimate the risk of mortality from metastatic renal cell carcinoma (mRCC). Outcomes from different therapies may vary within each risk group. These survival algorithms have been applied to assess out
Autor:
David F. McDermott, Sapna Pradyuman Patel, Gerald P Miletello, Brendan D. Curti, Ann W. Silk, Janice P. Dutcher, Rene Gonzalez, Mayer Fishman, Scott S. Tykodi, Elizabeth I. Buchbinder, Joseph I. Clark, Gregory A. Daniels, Shernan G. Holtan, Christopher D. Lao, John M. Richart
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Background Metastatic melanoma (mM) and renal cell carcinoma (mRCC) are often treated with anti-PD-1 based therapy, however not all patients respond and further therapies are needed. High dose interleukin-2 (HD IL-2) can lead to durable responses in
Autor:
Sanjiv S. Agarwala, Bret Taback, Venkatesh Rudraptna, Jessica C. Perritt, Janice P. Dutcher, John M. Richart, Neeraj Agarwal, Tharak B. Rao, Mayer Fishman, Howard L. Kaufman, Mohammed M. Milhem, Gregory A. Daniels, Lionel D. Lewis, Ralph J. Hauke, Peter J. Van Veldhuizen, Asim Amin, Gerald P Miletello, Lee D. Cranmer, Rene Gonzalez, David F. McDermott, Michael K.K. Wong, Ulka N. Vaishampayan, Sigrun Hallmeyer, Jose Lutzky, Michael A. Morse, Brendan D. Curti, Sapna Pradyuman Patel, Sandra Aung, Marc S. Ernstoff, Jonathan S. Treisman, Joseph I. Clark, Hong Hua, John H. Stewart, Joanne M. Jeter
Publikováno v:
Clinical genitourinary cancer
ProleukinR Observational Study to Evaluate the Treatment Patterns and Clinical Response in Malignancy (PROCLAIMSM) is the largest observational clinical database of high-dose interleukin-2 (HD IL-2)-treated patients in the US. Herein, the survival an
Autor:
David F. McDermott, James N. Lowder, Brendan D. Curti, Sandra Aung, Asim Amin, Michael K.K. Wong, Sanjiv S. Agarwala, Ajjai Alva, Rene Gonzalez, Gerald P Miletello, Ralph J. Hauke, John M. Kirkwood, Janice P. Dutcher, Michael A. Morse, Theodore F. Logan, Mayer Fishman, Gregory A. Daniels, Howard L. Kaufman, Neeraj Agarwal, Joseph I. Clark, Hong Hua
Publikováno v:
Cancer Immunology, Immunotherapy
High-dose interleukin-2 (HD IL-2) was approved for treatment of metastatic renal cell carcinoma (mRCC) in 1992 and for metastatic melanoma (mM) in 1998, in an era predating targeted therapies and immune checkpoint inhibitors. The PROCLAIMSM registry
Publikováno v:
Journal for Immunotherapy of Cancer
Meeting abstracts Recent studies have reported that the clinical benefit of interleukin-2 (IL-2) immunotherapy for metastatic renal cell carcinoma (mRCC) and melanoma (mM) may be underestimated by typically reported outcomes, instead suggesting that